MC2 Therapeutics launches psoriasis cream in US

The pharmaceutical firm has worked with partner Epi Health to launch Wynzora on the US market, where it was authorized as a treatment for psoriasis last year.
Jesper J. Lange, CEO of MC2 Therapeutics | Photo: MC2 Therapeutics/PR
Jesper J. Lange, CEO of MC2 Therapeutics | Photo: MC2 Therapeutics/PR
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY CATHERINE BRETT

Just under a year after MC2 Therapeutics received approval from the FDA for its psoriasis cream Wynzora, the treatment has been launched on the US market, the company reports in a press release.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading